Large international study finds diabetes drug cuts cardiovascular and kidney problems
(McMaster University) A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with type 2 diabetes.During more than five years of follow-up, cardiovascular events like heart attacks and strokes were reduced by 12% in people taking dulaglutide compared to people taking a placebo. This effect was seen in both men and women with or without previous cardiovascular disease.
In conclusions, dairy may be part of a healthy diet; however, additional studies exploring confounding factors are needed to ascertain the potential detrimental effects. PMID: 31199182 [PubMed - as supplied by publisher]
Authors: Tanner C, Wang G, Liu N, Andrikopoulos S, Zajac JD, Ekinci EI Abstract ■Metformin is recommended as first-line therapy for type 2 diabetes because of its safety, low cost and potential cardiovascular benefits. ■The use of metformin was previously restricted in people with chronic kidney disease (CKD) - a condition that commonly coexists with diabetes - due to concerns over drug accumulation and metformin-associated lactic acidosis. ■There are limited data from observational studies and small randomised controlled trials to suggest that metformin, independent of its antihyperglycaemic effects, may be ...
(The Lancet) A personalized active lifestyle program for employees with metabolic syndrome (who are at high risk of heart disease, stroke, and type 2 diabetes) that uses wearable activity trackers, a smartphone app, and face-to-face sessions with exercise coaches, can reduce disease severity in both men and women in various occupations, according to a randomized trial of over 300 workers published in The Lancet Public Health journal.
A study of twins in Sweden links a 30% higher risk in older age of brain artery blockage, which stroke often follows, to type 2 diabetes in middle age.
Conclusion: A delay of GE was associated with an increased incidence of cardiovascular events in diabetic subjects with chronic UGI symptoms. PMID: 31177651 [PubMed - as supplied by publisher]
AbstractAimsTo determine the potential risk factors and construct the predictive model of diabetic risk among a relatively low risk middle-aged and elderly Chinese population.MethodsInformation of participants was collected in the Dongfeng-Tongji cohort study, a perspective cohort study of Chinese occupational population. The main outcome was incident type 2 diabetes (T2DM). Based on the conventional risk factors of diabetes, we defined low risk participants without underlying diseases such as coronary heart disease, stroke, cancer, dyslipidemia, hypertension, metabolic syndrome, obesity and family history of diabetes. Tot...
Type 2 diabetes in midlife is associated with a 30% increased risk of a serious blockage of the brain arteries, often leading to stroke, and a doubling of the risk of narrowing of arteries in those over 60.
TYPE 2 diabetes is formally known as adult-onset diabetes and involves high blood sugar, insulin resistance and a lack of insulin. Long term complications could mean life threatening issues such as heart disease, strokes and diabetic retinopathy. Professor Francesco Rubino offers his tips to help reverse the symptoms of type 2 diabetes.
Full results of REWIND show dulaglutide significantly reduces CV events in patients with type 2 diabetes who primarily have CVD risk factors, rather than CVD itself. The major effect seems to be on stroke.Medscape Medical News
Publication date: Available online 9 June 2019Source: The LancetAuthor(s): Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Fady T Botros, Matthew C Riddle, Lars Rydén, Denis Xavier, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Purnima Rao-Melacini, Gloria Wong, Alvaro Avezum, Jan Basile, Namsik Chung, Ignacio CongetSummaryBackgroundTwo glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulag...